Last reviewed · How we verify
Flumetiazid — Competitive Intelligence Brief
phase 2
flumethiazide
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Flumetiazid (FLUMETHIAZIDE). Flumethiazide works by blocking the reabsorption of sodium and chloride ions in the kidneys, leading to increased urine production and reduced blood pressure.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Flumetiazid TARGET | FLUMETHIAZIDE | phase 2 | flumethiazide |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (flumethiazide class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Flumetiazid CI watch — RSS
- Flumetiazid CI watch — Atom
- Flumetiazid CI watch — JSON
- Flumetiazid alone — RSS
- Whole flumethiazide class — RSS
Cite this brief
Drug Landscape (2026). Flumetiazid — Competitive Intelligence Brief. https://druglandscape.com/ci/flumethiazide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing